$1.14 Billion is the total value of JOHNSON & JOHNSON's 25 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ILMN | New | ILLUMINA, INC. | $328,613,000 | – | 810,170 | +100.0% | 28.83% | – |
| ARWR | New | ARROWHEAD PHARMACEUTICALS | $203,576,000 | – | 3,260,869 | +100.0% | 17.86% | – |
| FATE | New | FATE THERAPEUTICS, INC. | $200,277,000 | – | 3,379,064 | +100.0% | 17.57% | – |
| LEGN | New | LEGEND BIOTECH CORPORATIONsponsored ads | $82,371,000 | – | 1,629,173 | +100.0% | 7.23% | – |
| New | CUE HEALTH, INC. | $65,532,000 | – | 5,548,864 | +100.0% | 5.75% | – | |
| CVRX | New | CVRX, INC. | $57,817,000 | – | 3,495,575 | +100.0% | 5.07% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC. | $43,400,000 | – | 2,449,183 | +100.0% | 3.81% | – |
| New | PROCEPT BIOROBOTICS CORPORATION | $38,855,000 | – | 1,018,478 | +100.0% | 3.41% | – | |
| MGTX | New | MEIRAGTX HOLDINGS PLC | $38,203,000 | – | 2,898,550 | +100.0% | 3.35% | – |
| FUSN | New | FUSION PHARMACEUTICALS INC. | $29,070,000 | – | 3,670,516 | +100.0% | 2.55% | – |
| VOR | New | VOR BIOPHARMA, INC. | $16,851,000 | – | 1,074,658 | +100.0% | 1.48% | – |
| PNT | New | POINT BIOPHARMA GLOBAL INC. | $7,690,000 | – | 1,000,000 | +100.0% | 0.68% | – |
| PHGE | New | BIOMX INC. | $6,528,000 | – | 2,133,402 | +100.0% | 0.57% | – |
| ACET | New | ADICET BIO, INC. | $5,715,000 | – | 728,944 | +100.0% | 0.50% | – |
| PHAS | New | PHASEBIO PHARMACEUTICALS, INC. | $4,998,000 | – | 1,607,044 | +100.0% | 0.44% | – |
| New | SOMALOGIC, INC. | $3,482,000 | – | 281,052 | +100.0% | 0.30% | – | |
| ALDX | New | ALDEYRA THERAPEUTICS, INC. | $3,467,000 | – | 394,834 | +100.0% | 0.30% | – |
| CSLT | New | CASTLIGHT HEALTH INC.cl b | $1,274,000 | – | 811,295 | +100.0% | 0.11% | – |
| NPCE | New | NEUROPACE, INC. | $879,000 | – | 55,435 | +100.0% | 0.08% | – |
| TCON | New | TRACON PHARMACEUTICALS, INC. | $325,000 | – | 84,003 | +100.0% | 0.03% | – |
| CBIO | New | CATALYST BIOSCIENCES, INC. | $275,000 | – | 66,951 | +100.0% | 0.02% | – |
| ZY | New | ZYMERGEN INC. | $218,000 | – | 16,553 | +100.0% | 0.02% | – |
| LUNG | New | PULMONX CORPORATION | $203,000 | – | 5,639 | +100.0% | 0.02% | – |
| SENS | New | SENSEONICS HOLDINGS, INC. | $185,000 | – | 54,621 | +100.0% | 0.02% | – |
| GRAY | New | GRAYBUG VISION, INC. | $164,000 | – | 49,547 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Johnson & Johnson Innovation - JJDC, Inc. #1
- Johnson & Johnson UK Treasury Company Limited #2
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORPORATION | 9 | Q3 2023 | 25.6% |
| FATE THERAPEUTICS, INC. | 9 | Q3 2023 | 24.8% |
| PROTAGONIST THERAPEUTICS INC. | 9 | Q3 2023 | 21.0% |
| CVRX, INC. | 9 | Q3 2023 | 19.5% |
| MEIRAGTX HOLDINGS PLC | 9 | Q3 2023 | 13.9% |
| Arrowhead Pharmaceuticals, Inc. | 9 | Q3 2023 | 24.6% |
| PROCEPT BIOROBOTICS CORPORATION | 9 | Q3 2023 | 10.5% |
| CUE HEALTH, INC. | 9 | Q3 2023 | 8.5% |
| FUSION PHARMACEUTICALS INC. | 9 | Q3 2023 | 5.4% |
| POINT BIOPHARMA GLOBAL INC. | 9 | Q3 2023 | 2.8% |
View JOHNSON & JOHNSON's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Fusion Pharmaceuticals Inc. | January 27, 2023 | 3,670,516 | 8.2% |
| Protagonist Therapeutics, Inc | January 11, 2023 | 2,449,183 | 5.0% |
| MeiraGTx Holdings plc | November 14, 2022 | 6,641,064 | 13.7% |
| PhaseBio Pharmaceuticals Inc | February 01, 2022 | 1,607,044 | 3.3% |
| Provention Bio, Inc. | January 17, 2020 | 1,124,973 | 2.4% |
| ADURO BIOTECH, INC. | January 22, 2019 | 3,906,207 | 4.9% |
| Aldeyra Therapeutics, Inc. | January 22, 2019 | 1,050,292 | 4.0% |
| GI DYNAMICS, INC. | January 22, 2019 | 565,569 | 3.7% |
| MACROGENICS INC | January 22, 2019 | 1,923,077 | 4.6% |
| Merus N.V. | January 22, 2019 | ? | ? |
View JOHNSON & JOHNSON's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 8-K/A | 2024-04-16 |
| 8-K | 2024-04-16 |
| 3 | 2024-04-10 |
| SC 13G | 2024-04-10 |
| DFAN14A | 2024-04-05 |
| PX14A6G | 2024-03-27 |
| 144 | 2024-03-13 |
| 4 | 2024-03-13 |
| ARS | 2024-03-13 |
| DEF 14A | 2024-03-13 |
View JOHNSON & JOHNSON's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.